Platelet-rich plasma combined with intralesional triamcinolone acetonide for the treatment of alopecia areata: A case report

Mubki, Thamer

doi:10.1016/j.jdds.2015.11.002

Cited by 22 publications

(22 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Following our previous work (43) several published works have been reported as regards efficacy of autologous PRP in AA (64)(65)(66)(67)(68)(69). The product under study represents the first biotechnological designed PRP able to reproduce the efficacy of autologous PRP.…”

Section: Discussionmentioning

confidence: 94%

Randomized controlled trial on a PRP-like cosmetic, biomimetic peptides based, for the treatment of alopecia areata

Rinaldi

Mora

Pinto

et al. 2019

Journal of Dermatological Treatment

View full text Add to dashboard Cite

Background: Alopecia areata (AA) is a non-scarring auto-immune hair disorder. Recent researches explained the role of growth factors (GFs) in hair follicle cycling. The main reservoir of GFs are alpha-granules of platelets and novel procedures have been implemented aimed at collecting platelet-rich plasma (PRP). PRP has been safely implemented in many medical applications and has also been successfully used as alternative cell-based therapy for the treatment of hair growth disorders, among which also AA. Objectives: By means of a randomized double-blinded, placebo and active-controlled, parallel group study we have studied the efficacy of a cosmetic product (named TR-M-PRP plus) comprising biomimetic peptides specific for hair growth, mimicking PRP composition for the treatment of AA. Subjects were treated for three months and evaluated, at the end of the study and after one month of follow-up, as regards hair growth using SALT score. Results: TR-M-PRP plus-like topic produced a statistically significant (p < .001) clinical improvement in SALT score after 3 months of therapy, compared to baseline. Hair growth results further improved after 1 month of follow-up. Conclusions: This clinical investigation suggests that the biotechnological designed PRP-like cosmetic could represent a valid and safer alternative to autologous PRP for the treatment of AA.

show abstract

Section: Discussionmentioning

confidence: 94%

Randomized controlled trial on a PRP-like cosmetic, biomimetic peptides based, for the treatment of alopecia areata

Rinaldi

Mora

Pinto

et al. 2019

Journal of Dermatological Treatment

View full text Add to dashboard Cite

show abstract

“…Consistent with these findings, we demonstrated that tofacitinib inhibits the viability of CD4 + T cells in dose dependent manner. Triamcinolone is anti-inflammatory steroid which have therapeutic significance for the treatment of various inflammatory autoimmune diseases 53 . It has been reported that triamcinolone decreases the viability of human lens epithelial cells through apoptotic pathway 54 .…”

Section: Discussionmentioning

confidence: 99%

Amelioration of Experimental autoimmune encephalomyelitis and DSS induced colitis by NTG-A-009 through the inhibition of Th1 and Th17 cells differentiation

Acharya

Timilshina

Jiang

et al. 2018

Sci Rep

View full text Add to dashboard Cite

CD4+ T cells are the central for the mammalian adaptive immune system. Naïve CD4+ T cells mainly differentiate in to pro-inflammatory Th1, Th2 and Th17 cells upon antigenic stimulation. IFN-γ secreting Th1 cells and IL-17 secreting Th17 cells are found to play key roles in autoimmune diseases like multiple sclerosis (MS) and ulcerative colitis (UC). In this study we found NTG-A-009, 6-aminopyridin-3-ol, has great inhibitory effect on in vitro differentiation of Th1 and Th17 cells without affecting regulatory T cells. Moreover, NTG-A-009 had no effect on CD4+ T cell proliferation and viability. In vivo treatment has shown that NTG-A-009 has ameliorated experimental autoimmune encephalomyelitis (EAE) and dextran sulfate sodium (DSS) induced colitis through the inhibition of Th1 and Th17 cells differentiation. Mechanistically, NTG-A-009 suppressed Th1 and Th17 cells differentiation via the modulation of JAK/STAT signaling pathway. Thus, our data demonstrated that NTG-A-009 ameliorated inflammation through the inhibition of Th1 and Th17 cells generation making it a potential therapeutic candidate for the treatment of inflammatory diseases.

show abstract

“…Alopecia areata management has also been the object of the combination treatment with PRP plus triamcinolone acetonide (TrA), a corticosteroid that is usually used in dermatological conditions such as psoriasis and dermatitis. After 16 weeks, a significant increase in mean hair diameter was achieved . These autologous platelet derived proteins have additionally been used as an adjuvant treatment during some surgical techniques such as follicular unit extraction surgery (FUE).…”

Section: Prp: the Perfect Partner To Combine With?mentioning

confidence: 99%

Platelet rich plasma for the management of hair loss: Better alone or in combination?

Anitua

Pino

Jaén

et al. 2018

J of Cosmetic Dermatology

View full text Add to dashboard Cite

Platelet-rich plasma (PRP) and autologous protein-based treatments have recently emerged as a potential therapeutic approach for hair loss-related disorders including androgenetic alopecia and alopecia areata. The safety and efficacy of repeated intradermal injections of PRP has proved to promote hair growth in a number of randomized clinical trials. Biologically active proteins and cytokines released upon platelet activation have shown to induce folliculogenesis and activate the anagen growing phase of dormant bulbs. Interestingly, further studies have revealed that combining PRP with other hair loss-related products may enhance the final performance of the treatment. These synergistic approaches include Food and Drug Administration (FDA) approved drugs such as finasteride or minoxidil, bioactive macromolecules and cell-based therapies. Here, recent research involving alone or combined therapy with platelet-rich plasma for the management of hair loss-related disorders are outlined and future prospects are discussed.

show abstract

Platelet-rich plasma combined with intralesional triamcinolone acetonide for the treatment of alopecia areata: A case report

Cited by 22 publications

References 9 publications

Randomized controlled trial on a PRP-like cosmetic, biomimetic peptides based, for the treatment of alopecia areata

Randomized controlled trial on a PRP-like cosmetic, biomimetic peptides based, for the treatment of alopecia areata

Amelioration of Experimental autoimmune encephalomyelitis and DSS induced colitis by NTG-A-009 through the inhibition of Th1 and Th17 cells differentiation

Platelet rich plasma for the management of hair loss: Better alone or in combination?

Contact Info

Product

Resources

About